FLT3 and acute myeloid leukemia: Updated results from the latter randomized phase-III trial in relapsed/refractory AML patients with FLT3-ITD mutation have recently been updated and show prolonged overall survival 0.76 (95% CI, 0.58–0.98; p = 0.0177) and a higher composite complete remission (CR) rate (48% vs. 27%) for Quizartinib in comparison to salvage chemotherapy.